Cargando...
SGLT2-Inhibitoren: Was gibt es Neues?
Sodium-glucose transport protein 2 inhibitors (SGLT2i, gliflozins) were originally developed for the treatment of type 2 diabetes; however, in mandatory approval studies, they demonstrated unexpected positive effects on cardiovascular endpoints and renal function. Several phase III studies published...
Gardado en:
| Publicado en: | Nephrologe |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Springer Medizin
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8245922/ https://ncbi.nlm.nih.gov/pubmed/34226841 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11560-021-00511-4 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|